Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 陈德章教授 (肿瘤学系) |
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1097/01.cpm.0000059369.04504.d5 |
引用次数
Scopushttp://aims.cuhk.edu.hk/converis/portal/Publication/0Scopus source URL
其它资讯
摘要The new generation of cytotoxic drugs, such as gemcitabine, docetaxel, paclitaxel, vinorelbine, and irinotecan, plays an crucial role in the management of advanced non-small cell lung cancer. Single-agent therapy has been shown to palliate symptoms, improve quality of life, and defer radiotherapy, but does not necessarily prolong survival in chemotherapy-na?ve patients. On the other hand, single-agent docetaxel may prolong survival when given as second-line therapy in patients who have failed platinum-based regimens. Many phase II studies have demonstrated that the gemcitabine- or taxane-based nonplatinum combinations are highly effective in the induction of tumor response and are able to attain survival prolongation. Two published randomized phase III studies comparing nonplatinum-based to platinum-based chemotherapy have reported equal efficacy, but interim results from two other ongoing comparative studies have suggested the nonplatinum-based regimens to be inferior. The current available data do not necessarily support general use of nonplatinum-based regimens in patients with advanced non-small cell lung cancer, but selected patients may benefit.
着者Mok T.S.K., Chan A.T.C.
期刊名称Clinical Pulmonary Medicine
出版年份2http://aims.cuhk.edu.hk/converis/portal/Publication/0http://aims.cuhk.edu.hk/converis/portal/Publication/03
月份5
日期1
卷号1http://aims.cuhk.edu.hk/converis/portal/Publication/0
期次3
出版社Lippincott Williams & Wilkins Ltd.
出版地United States
页次143 - 153
国际标準期刊号1http://aims.cuhk.edu.hk/converis/portal/Publication/068-http://aims.cuhk.edu.hk/converis/portal/Publication/064http://aims.cuhk.edu.hk/converis/portal/Publication/0
语言英式英语
关键词Gemcitabine, Irinotecan, Non-platinum-based chemotherapy, Non-small cell lung cancer, Platinum-based chemotherapy, Taxane, Vinorelbine
